pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$VTGNVistagen Therapeutics, Inc.

$VTGN
South San Francisco, CA, USupdated 2mo ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 2: 4Phase 3: 1
4Phase 21Phase 3
Phase 3
fasedienol
Social Anxiety Disorder (SAD/Social Phobia)
Phase 2
AV-101
Major Depressive Disorder
Glutamate [NMDA] receptor
Phase 2
PH-15
Cognitive Impairment
Phase 2
itruvone
Major Depressive Disorder
Phase 2
refisolone
Premenstrual Dysphoric Disorder (PMDD)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)recruitingn=236
  • phase2PH94B in the Treatment of Adjustment Disorder With Anxietycompletedn=41
  • phase2A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorderrecruitingn=60
  • phase3Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)active not recruitingn=238
  • phase3PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2terminatedn=228
  • phase3Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)terminatedn=481
  • phase3PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challengecompletedn=224

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Apr 7, 26grantTressler Nick B. · Chief Financial Officer75,000 sh
  • Apr 7, 26grantSingh Shawn · President and CEO3,732 sh
  • Apr 7, 26grantSingh Shawn · President and CEO71,268 sh
  • Apr 7, 26grantPrince Joshua S. · Chief Operating Officer18,752 sh
  • Apr 7, 26grantPrince Joshua S. · Chief Operating Officer56,248 sh
  • Apr 7, 26grantCote Elissa S. · Chief Corp Development Officer75,000 sh
🐶 Hiring Signal
No open roles indexed yet — view Vistagen Therapeutics, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$VTGN
SEC CIK
0001411685
country
US
source
sec_tickers
top tags
Major Depression2Women's Health1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?